Part V: Amino Acid & Nucleotide Metabolism

Amino acids serve as the building blocks of proteins, but their metabolic roles extend far beyond structural functions. They are precursors for neurotransmitters, hormones, heme, nucleotides, and other nitrogen-containing molecules. This part covers the catabolism and biosynthesis of amino acids, the urea cycle for nitrogen disposal, the fates of carbon skeletons, and the metabolism of purine and pyrimidine nucleotides — including clinically important targets for chemotherapy.

Chapter 23: Amino Acid Catabolism

The human body continuously turns over its protein content. Each day, approximately 300–400 g of body protein is degraded and resynthesized. The amino acids released by proteolysis enter a common amino acid pool that also receives dietary amino acids absorbed from the gut. This pool supplies substrates for new protein synthesis, energy production, and the biosynthesis of specialized nitrogen-containing molecules.

23.1 Protein Turnover and the Amino Acid Pool

Unlike carbohydrates and lipids, amino acids are not stored in dedicated reserve forms. The body maintains a dynamic free amino acid pool of roughly 70–100 g distributed between plasma and intracellular compartments. This pool is constantly replenished by three sources: dietary protein digestion, endogenous protein degradation, and de novo amino acid synthesis (for nonessential amino acids). Amino acids leave the pool through protein synthesis, conversion to specialized products, or catabolism for energy.

When amino acids are catabolized, the first step is almost always removal of the amino group. The resulting carbon skeletons can then enter central metabolic pathways (gluconeogenesis, ketogenesis, or the TCA cycle). The nitrogen must be safely disposed of, primarily as urea in ureotelic organisms like humans.

Key Concept: Nitrogen Balance

Nitrogen balance is the difference between nitrogen intake (dietary protein) and nitrogen excretion (urea, ammonia, creatinine, uric acid). A healthy adult is in nitrogen equilibrium. Positive nitrogen balance occurs during growth, pregnancy, and recovery from illness. Negative nitrogen balance indicates protein wasting — as seen in starvation, trauma, or uncontrolled diabetes.

23.2 Transamination: The Central Nitrogen-Shuffling Reaction

Transamination is the reversible transfer of an amino group from an amino acid to an \(\alpha\)-keto acid, catalyzed by enzymes called aminotransferases (also known as transaminases). These enzymes require pyridoxal phosphate (PLP), the active form of vitamin B\(_6\), as a coenzyme.

The general transamination reaction is:

\[\text{Amino acid}_1 + \alpha\text{-Keto acid}_2 \rightleftharpoons \alpha\text{-Keto acid}_1 + \text{Amino acid}_2\]

The two most clinically important aminotransferases are:

Alanine aminotransferase (ALT/GPT): \(\text{Alanine} + \alpha\text{-Ketoglutarate} \rightleftharpoons \text{Pyruvate} + \text{Glutamate}\)
Aspartate aminotransferase (AST/GOT): \(\text{Aspartate} + \alpha\text{-Ketoglutarate} \rightleftharpoons \text{Oxaloacetate} + \text{Glutamate}\)

Notice that in both reactions, \(\alpha\)-ketoglutarate is the amino group acceptor, generating glutamate. This makes glutamate the central collection point for amino nitrogen in the cell.

Mathematical Deep Dive: PLP Mechanism

The PLP mechanism proceeds through a series of aldimine and ketimine intermediates. The equilibrium constant for the overall transamination is close to 1.0, reflecting the symmetry of the reaction:

\[K_{eq} = \frac{[\alpha\text{-Keto acid}_1][\text{Amino acid}_2]}{[\text{Amino acid}_1][\alpha\text{-Keto acid}_2]} \approx 1.0\]

The reaction proceeds in two half-reactions (ping-pong mechanism). In the first half-reaction, PLP accepts the amino group from amino acid\(_1\) to form pyridoxamine phosphate (PMP) and \(\alpha\)-keto acid\(_1\). In the second half-reaction, PMP donates the amino group to \(\alpha\)-keto acid\(_2\), regenerating PLP and producing amino acid\(_2\).

23.3 Oxidative Deamination: Glutamate Dehydrogenase

The amino groups funneled into glutamate by transamination must ultimately be released as free ammonium ions (\(\text{NH}_4^+\)). This is accomplished by glutamate dehydrogenase (GDH), a mitochondrial enzyme that catalyzes the oxidative deamination of glutamate:

\[\text{Glutamate} + \text{NAD}^+ (\text{or NADP}^+) + \text{H}_2\text{O} \rightleftharpoons \alpha\text{-Ketoglutarate} + \text{NH}_4^+ + \text{NADH} (\text{or NADPH})\]

GDH is one of the few enzymes that can use either \(\text{NAD}^+\) or \(\text{NADP}^+\) as the electron acceptor. It operates at a key metabolic crossroads and is allosterically regulated:

Activated by: ADP (signals low energy charge)
Inhibited by: GTP (signals high energy charge)

The \(\text{NH}_4^+\) released by GDH in the liver enters the urea cycle directly. In peripheral tissues, ammonia is transported to the liver as glutamine (via glutamine synthetase) or as alanine (via the glucose-alanine cycle from muscle).

23.4 Amino Acid Decarboxylation and Biogenic Amines

Certain amino acids undergo decarboxylation (also PLP-dependent) to produce biologically active amines:

Amino Acid	Biogenic Amine	Function
Histidine	Histamine	Inflammation, gastric acid secretion
Tryptophan	Serotonin (5-HT)	Mood, sleep, vasoconstriction
Tyrosine	Dopamine, Norepinephrine, Epinephrine	Neurotransmission, fight-or-flight
Glutamate	GABA (\(\gamma\)-aminobutyrate)	Inhibitory neurotransmitter
Serine	Ethanolamine	Phospholipid synthesis

The general decarboxylation reaction:

\[\text{Amino acid} \xrightarrow{\text{PLP}} \text{Amine} + \text{CO}_2\]

23.5 One-Carbon Metabolism

Several amino acids (serine, glycine, histidine, tryptophan) donate one-carbon units to tetrahydrofolate (THF), the active form of folic acid (vitamin B\(_9\)). These one-carbon units exist at different oxidation states on THF:

\(N^{5}\)-methyl-THF (most reduced)
\(N^{5},N^{10}\)-methylene-THF
\(N^{5},N^{10}\)-methenyl-THF
\(N^{10}\)-formyl-THF (most oxidized)

The primary entry point is the serine hydroxymethyltransferase reaction:

\[\text{Serine} + \text{THF} \rightleftharpoons \text{Glycine} + N^{5},N^{10}\text{-Methylene-THF} + \text{H}_2\text{O}\]

S-Adenosylmethionine (SAM) is another crucial one-carbon carrier that serves as the universal methyl donor. SAM is synthesized from methionine and ATP by methionine adenosyltransferase. After donating its methyl group, SAM becomes S-adenosylhomocysteine (SAH), which is hydrolyzed to homocysteine. Homocysteine can be remethylated back to methionine using \(N^5\)-methyl-THF (catalyzed by methionine synthase, which requires vitamin B\(_{12}\)) or converted to cysteine via the transsulfuration pathway.

Clinical Correlation: Folate and B12 Deficiency

Deficiency of folate or vitamin B\(_{12}\) leads to megaloblastic anemia due to impaired thymidylate synthesis (a one-carbon transfer reaction essential for DNA synthesis). The “methyl trap hypothesis” explains why B\(_{12}\) deficiency mimics folate deficiency: without B\(_{12}\), folate becomes trapped as \(N^5\)-methyl-THF and cannot be recycled to other active forms. B\(_{12}\) deficiency also causes neurological damage (subacute combined degeneration of the spinal cord) due to impaired methylation reactions in myelin synthesis.

Chapter 24: The Urea Cycle

The urea cycle (ornithine cycle) was the first cyclic metabolic pathway discovered, elucidated by Hans Krebs and Kurt Henseleit in 1932 — five years before the citric acid cycle. It converts toxic ammonia into urea, a water-soluble, non-toxic molecule that is excreted by the kidneys. The cycle operates exclusively in the liver, with two reactions occurring in the mitochondrial matrix and three in the cytosol.

Key Concept: Two Nitrogen Sources of Urea

Each urea molecule contains two nitrogen atoms. One comes from free \(\text{NH}_4^+\) (via carbamoyl phosphate), and the other comes from aspartate. The carbon atom of urea derives from \(\text{CO}_2\). This arrangement means that the urea cycle is intimately linked to the TCA cycle through aspartate and fumarate.

24.1 The Five Reactions of the Urea Cycle

Reaction 1: Carbamoyl Phosphate Synthetase I (CPS-I)

This mitochondrial enzyme catalyzes the ATP-dependent condensation of ammonia and bicarbonate to form carbamoyl phosphate. It is the rate-limiting step of the urea cycle and requires N-acetylglutamate (NAG) as an obligate allosteric activator.

\[\text{NH}_4^+ + \text{HCO}_3^- + 2\text{ATP} \xrightarrow{\text{CPS-I}} \text{Carbamoyl phosphate} + 2\text{ADP} + \text{P}_i\]

Note that two ATP molecules are consumed: one to activate bicarbonate (forming carboxyphosphate) and the second to phosphorylate carbamate. CPS-I is distinct from CPS-II, which is cytosolic and uses glutamine (not free \(\text{NH}_4^+\)) for pyrimidine biosynthesis.

Reaction 2: Ornithine Transcarbamoylase (OTC)

Also mitochondrial, this enzyme transfers the carbamoyl group from carbamoyl phosphate to ornithine, forming citrulline:

\[\text{Ornithine} + \text{Carbamoyl phosphate} \rightarrow \text{Citrulline} + \text{P}_i\]

Citrulline is then transported out of the mitochondria to the cytosol via a specific transporter (ornithine-citrulline antiporter).

Reaction 3: Argininosuccinate Synthetase

In the cytosol, citrulline condenses with aspartate (the second nitrogen donor) in an ATP-dependent reaction:

\[\text{Citrulline} + \text{Aspartate} + \text{ATP} \rightarrow \text{Argininosuccinate} + \text{AMP} + \text{PP}_i\]

This reaction consumes the equivalent of 2 ATP (since \(\text{PP}_i\) is hydrolyzed to 2\(\text{P}_i\) by pyrophosphatase, driving the reaction to completion).

Reaction 4: Argininosuccinate Lyase

Argininosuccinate is cleaved to arginine and fumarate:

\[\text{Argininosuccinate} \rightarrow \text{Arginine} + \text{Fumarate}\]

The fumarate produced here links the urea cycle to the TCA cycle. Fumarate is hydrated to malate by cytosolic fumarase, and malate can be oxidized to oxaloacetate by malate dehydrogenase. Oxaloacetate can then be transaminated back to aspartate, completing the aspartate-argininosuccinate shunt.

Reaction 5: Arginase

The final reaction hydrolyzes arginine to produce urea and regenerate ornithine:

\[\text{Arginine} + \text{H}_2\text{O} \rightarrow \text{Urea} + \text{Ornithine}\]

Ornithine is transported back into the mitochondria to begin another turn of the cycle. Urea diffuses into the blood and is filtered by the kidneys for excretion. A normal adult excretes about 25–30 g of urea per day.

Mathematical Deep Dive: Net Reaction and Energetics

Summing all five reactions gives the net equation of the urea cycle:

\[\text{NH}_4^+ + \text{CO}_2 + \text{Aspartate} + 3\text{ATP} + 3\text{H}_2\text{O} \rightarrow \text{Urea} + \text{Fumarate} + 2\text{ADP} + \text{AMP} + 4\text{P}_i\]

The energy cost is effectively 4 high-energy phosphate bonds per urea molecule (2 ATP \(\rightarrow\) 2 ADP in reaction 1, plus 1 ATP \(\rightarrow\) AMP + PP\(_i\) in reaction 3, where PP\(_i \rightarrow\) 2P\(_i\)).

However, the oxidation of fumarate to oxaloacetate (via the TCA cycle link) generates 1 NADH \(\approx\) 2.5 ATP, partially offsetting this cost. The net expense is therefore approximately \(4 - 2.5 = 1.5\) ATP equivalents per urea produced.

24.2 Regulation of the Urea Cycle

Regulation occurs at multiple levels:

N-Acetylglutamate (NAG): Synthesized from acetyl-CoA and glutamate by N-acetylglutamate synthase (NAGS). NAG is an obligate allosteric activator of CPS-I. Arginine activates NAGS, providing feed-forward activation when amino acid catabolism is high.
Substrate availability: Increased dietary protein raises amino acid levels, increasing ammonia production and flux through the cycle.
Long-term enzyme induction: High-protein diets or prolonged starvation (when muscle protein is catabolized) upregulate expression of all five urea cycle enzymes.

Clinical Correlation: Urea Cycle Disorders

Genetic deficiencies in any of the five urea cycle enzymes cause hyperammonemia, which is neurotoxic. The most common deficiency is ornithine transcarbamoylase (OTC) deficiency, an X-linked disorder. Symptoms include vomiting, lethargy, and cerebral edema in neonates.

Diagnosis involves measuring plasma amino acids and urinary orotic acid:

CPS-I deficiency: elevated \(\text{NH}_4^+\), low citrulline, no orotic aciduria
OTC deficiency: elevated \(\text{NH}_4^+\), low citrulline, orotic aciduria (carbamoyl-P diverted to pyrimidine pathway)
Argininosuccinate synthetase deficiency (citrullinemia): elevated citrulline
Argininosuccinate lyase deficiency: elevated argininosuccinate
Arginase deficiency: elevated arginine

Treatment includes protein restriction, administration of sodium benzoate and sodium phenylbutyrate (which provide alternative nitrogen disposal pathways), and in severe cases, liver transplantation.

Chapter 25: Carbon Skeleton Fates

After the amino group is removed, the remaining carbon skeletons of the 20 standard amino acids are funneled into just seven metabolic intermediates: pyruvate, acetyl-CoA, acetoacetyl-CoA, \(\alpha\)-ketoglutarate, succinyl-CoA, fumarate, and oxaloacetate. Based on which intermediates they produce, amino acids are classified as glucogenic, ketogenic, or both.

Key Concept: Glucogenic vs. Ketogenic

Glucogenic amino acids yield pyruvate or TCA cycle intermediates (oxaloacetate, \(\alpha\)-ketoglutarate, succinyl-CoA, fumarate) that can be converted to glucose via gluconeogenesis.
Ketogenic amino acids yield acetyl-CoA or acetoacetyl-CoA, which can form ketone bodies but cannot produce net glucose (because acetyl-CoA cannot be converted to oxaloacetate in animals).
Both glucogenic and ketogenic: Isoleucine, phenylalanine, tryptophan, and tyrosine yield both types of intermediates.

25.1 Classification of All 20 Amino Acids

Category	Amino Acids	Product(s)
Glucogenic only	Ala, Gly, Ser, Cys, Thr	Pyruvate
	Asp, Asn	Oxaloacetate
	Glu, Gln, Pro, Arg, His	\(\alpha\)-Ketoglutarate
	Val, Met	Succinyl-CoA
	Ile (also ketogenic)	Succinyl-CoA + Acetyl-CoA
	Phe, Tyr (also ketogenic)	Fumarate + Acetoacetate
Both	Ile, Phe, Trp, Tyr	TCA intermediate + Acetyl-CoA/Acetoacetate
Ketogenic only	Leu, Lys	Acetyl-CoA + Acetoacetyl-CoA

A useful mnemonic for the purely ketogenic amino acids: only Leucine and Lysine are exclusively ketogenic. Remember “LL” for purely ketogenic.

25.2 Branched-Chain Amino Acid (BCAA) Degradation

The three BCAAs — valine, leucine, and isoleucine — share a common initial degradation pathway:

Transamination by branched-chain aminotransferase (BCAT) to the corresponding \(\alpha\)-keto acids
Oxidative decarboxylation by the branched-chain \(\alpha\)-keto acid dehydrogenase complex (BCKDH) — analogous to pyruvate dehydrogenase and \(\alpha\)-ketoglutarate dehydrogenase. Requires TPP, lipoamide, CoA, FAD, NAD\(^+\)
Further reactions diverge to yield specific products:
- Val \(\rightarrow\) succinyl-CoA (glucogenic)
- Leu \(\rightarrow\) acetyl-CoA + acetoacetate (ketogenic)
- Ile \(\rightarrow\) succinyl-CoA + acetyl-CoA (both)

\[\text{BCAA} + \alpha\text{-KG} \xrightarrow{\text{BCAT}} \alpha\text{-Keto acid} + \text{Glu} \xrightarrow{\text{BCKDH}} \text{Acyl-CoA derivative} + \text{CO}_2\]

25.3 Aromatic Amino Acid Degradation

Phenylalanine is first hydroxylated to tyrosine by phenylalanine hydroxylase (PAH), requiring tetrahydrobiopterin (BH\(_4\)) as a cofactor:

\[\text{Phe} + \text{O}_2 + \text{BH}_4 \xrightarrow{\text{PAH}} \text{Tyr} + \text{BH}_2 + \text{H}_2\text{O}\]

Tyrosine is then degraded through a series of reactions yielding fumarate and acetoacetate, making it both glucogenic and ketogenic. Tyrosine is also the precursor for DOPA, dopamine, norepinephrine, epinephrine, melanin, and thyroid hormones.

Tryptophan has the most complex degradation pathway of any amino acid. It is degraded via the kynurenine pathway, ultimately yielding alanine and acetoacetyl-CoA. Tryptophan is also the precursor for serotonin (5-hydroxytryptamine) and NAD\(^+\) (via the quinolinate pathway).

25.4 Sulfur Amino Acid Metabolism

Methionine is activated to SAM, donates its methyl group, and the resulting homocysteine either re-enters the methionine cycle (remethylation) or is converted to cysteine via the transsulfuration pathway (catalyzed by cystathionine \(\beta\)-synthase and cystathionine\(\gamma\)-lyase, both PLP-dependent). The sulfur from cysteine can be oxidized to sulfate or incorporated into iron-sulfur clusters, taurine, and other metabolites.

Clinical Correlation: Inborn Errors of Amino Acid Metabolism

Phenylketonuria (PKU): Autosomal recessive deficiency of phenylalanine hydroxylase. Phenylalanine accumulates and is transaminated to phenylpyruvate (a phenylketone excreted in urine). Without treatment (low-Phe diet from birth), severe intellectual disability results. PKU is detected by newborn screening (Guthrie test). The artificial sweetener aspartame contains phenylalanine, hence the warning labels.

Maple Syrup Urine Disease (MSUD): Deficiency of the BCKDH complex. Branched-chain \(\alpha\)-keto acids accumulate, giving urine a characteristic sweet odor. Leads to neurological damage and death if untreated. Treatment requires dietary restriction of BCAAs.

Homocystinuria: Most commonly due to cystathionine\(\beta\)-synthase deficiency. Homocysteine accumulates, causing lens subluxation (downward, unlike Marfan syndrome), intellectual disability, osteoporosis, and thromboembolism. Some patients respond to high-dose vitamin B\(_6\) (pyridoxine).

Alkaptonuria: Deficiency of homogentisate oxidase in the tyrosine degradation pathway. Homogentisic acid accumulates, polymerizes to a dark pigment (ochronosis), and is deposited in connective tissues. Urine turns dark on standing. One of the first inborn errors of metabolism described by Archibald Garrod (1902).

For Graduate Students: Amino Acid Catabolism in Cancer

Many tumors exhibit altered amino acid metabolism. Some cancers become “addicted” to specific amino acids: acute lymphoblastic leukemia (ALL) cells often lack asparagine synthetase and depend on exogenous asparagine — hence the therapeutic use of L-asparaginase, which depletes plasma asparagine. Glutamine metabolism is upregulated in many cancers (glutamine addiction), making glutaminase inhibitors (e.g., CB-839/telaglenastat) an active area of research. Serine/glycine biosynthesis is frequently amplified in tumors, with phosphoglycerate dehydrogenase (PHGDH) overexpression supporting nucleotide and lipid synthesis.

Chapter 26: Amino Acid Biosynthesis

Humans can synthesize only 11 of the 20 standard amino acids. The remaining 9 must be obtained from the diet and are termed essential amino acids. The distinction largely reflects the complexity of the biosynthetic pathways: those requiring many enzymatic steps tend to be essential because humans have lost the corresponding genes during evolution.

26.1 Essential vs. Nonessential Amino Acids

Essential (9)	Nonessential (11)	Conditionally Essential
His, Ile, Leu	Ala, Asp, Asn	Arg (growth, stress)
Lys, Met, Phe	Glu, Gln, Gly	Gln (critical illness)
Thr, Trp, Val	Pro, Ser, Cys, Tyr, Arg	Cys (premature infants)

Mnemonic for essential amino acids: “PVT TIM HALL” — Phe, Val, Thr, Trp, Ile, Met, His, Arg (conditionally), Leu, Lys. Note that Tyr is nonessential only if Phe is available (Tyr is synthesized from Phe), and Cys is nonessential only if Met is available (Cys is synthesized from Met via the transsulfuration pathway).

26.2 Biosynthetic Families

Nonessential amino acids are grouped into biosynthetic families based on their metabolic precursors:

From \(\alpha\)-Ketoglutarate: Glu, Gln, Pro, Arg

Glutamate is formed by reductive amination of\(\alpha\)-ketoglutarate by glutamate dehydrogenase (the reverse of oxidative deamination):

\[\alpha\text{-Ketoglutarate} + \text{NH}_4^+ + \text{NADPH} \rightarrow \text{Glutamate} + \text{NADP}^+ + \text{H}_2\text{O}\]

Glutamine is formed by ATP-dependent amidation of glutamate by glutamine synthetase:

\[\text{Glutamate} + \text{NH}_4^+ + \text{ATP} \xrightarrow{\text{Gln synthetase}} \text{Glutamine} + \text{ADP} + \text{P}_i\]

Proline is synthesized from glutamate via glutamate \(\gamma\)-semialdehyde (cyclization). Arginine is synthesized via the urea cycle (from ornithine, which derives from glutamate).

From Oxaloacetate: Asp, Asn

Aspartate is formed by transamination of oxaloacetate:

\[\text{Oxaloacetate} + \text{Glutamate} \xrightarrow{\text{AST}} \text{Aspartate} + \alpha\text{-Ketoglutarate}\]

Asparagine is formed by amidation of aspartate by asparagine synthetase, using glutamine as the nitrogen donor.

From Pyruvate: Ala

Alanine is formed by transamination of pyruvate (catalyzed by ALT):

\[\text{Pyruvate} + \text{Glutamate} \xrightarrow{\text{ALT}} \text{Alanine} + \alpha\text{-Ketoglutarate}\]

From 3-Phosphoglycerate: Ser, Gly, Cys

Serine is synthesized from 3-phosphoglycerate (a glycolytic intermediate) through oxidation, transamination, and dephosphorylation. The key enzyme is phosphoglycerate dehydrogenase (PHGDH). Glycine is derived from serine by serine hydroxymethyltransferase (donating a one-carbon unit to THF). Cysteine requires methionine (an essential amino acid) for its sulfur atom and serine for its carbon backbone, via the transsulfuration pathway.

From Phenylalanine: Tyr

Tyrosine is formed by hydroxylation of phenylalanine (an essential amino acid) by phenylalanine hydroxylase. Thus Tyr is nonessential only when dietary Phe is adequate.

For Graduate Students: The Shikimate Pathway

The aromatic amino acids (Phe, Tyr, Trp) are synthesized in plants and microorganisms via the shikimate pathway, which converts phosphoenolpyruvate (PEP) and erythrose-4-phosphate (from the pentose phosphate pathway) into chorismate, the common precursor for all three aromatic amino acids.

\[\text{PEP} + \text{Erythrose-4-P} \rightarrow \cdots \rightarrow \text{Chorismate} \rightarrow \begin{cases} \text{Prephenate} \rightarrow \text{Phe, Tyr} \\ \text{Anthranilate} \rightarrow \text{Trp} \end{cases}\]

The herbicide glyphosate (Roundup) inhibits 5-enolpyruvylshikimate-3-phosphate (EPSP) synthase, a key enzyme in this pathway. Since animals lack the shikimate pathway, glyphosate has low acute toxicity to mammals, though environmental and chronic health effects remain subjects of debate.

26.3 Nitrogen Fixation

The ultimate source of biologically available nitrogen is biological nitrogen fixation, carried out by certain prokaryotes (e.g., Rhizobium in legume root nodules, free-living Azotobacter). The enzyme nitrogenase catalyzes:

\[\text{N}_2 + 8\text{H}^+ + 8e^- + 16\text{ATP} \rightarrow 2\text{NH}_3 + \text{H}_2 + 16\text{ADP} + 16\text{P}_i\]

This is an extraordinarily energy-expensive process (16 ATP per \(\text{N}_2\) fixed). Nitrogenase is irreversibly inactivated by oxygen, which is why nitrogen-fixing organisms have elaborate mechanisms to maintain anaerobic conditions around the enzyme (e.g., leghemoglobin in root nodules).

26.4 Amino Acid-Derived Specialized Molecules

Amino acids serve as precursors for a remarkable array of biologically important molecules:

Precursor	Product	Function
Glycine	Heme (porphyrins)	Oxygen transport, electron transfer
Glycine, Arginine, Met	Creatine / Phosphocreatine	Rapid ATP regeneration in muscle
Glu, Cys, Gly	Glutathione (GSH)	Antioxidant defense, detoxification
Arginine	Nitric oxide (NO)	Vasodilation, signaling
Tryptophan	Serotonin, Melatonin, NAD\(^+\)	Neurotransmission, circadian rhythm
Tyrosine	Catecholamines, Melanin, T\(_3\)/T\(_4\)	Neurotransmission, pigmentation, thyroid
Histidine	Histamine	Allergic response, gastric acid

The synthesis of nitric oxide (NO) from arginine by nitric oxide synthase (NOS) is particularly noteworthy:

\[\text{Arginine} + \text{O}_2 + \text{NADPH} \xrightarrow{\text{NOS}} \text{Citrulline} + \text{NO} + \text{NADP}^+\]

NO activates guanylate cyclase, producing cGMP, which causes smooth muscle relaxation and vasodilation. This is the mechanism exploited by nitroglycerin (for angina) and sildenafil (Viagra, which inhibits cGMP phosphodiesterase).

Chapter 27: Nucleotide Metabolism

Nucleotides serve as the monomeric units of DNA and RNA, energy currency (ATP, GTP), signaling molecules (cAMP, cGMP), and components of coenzymes (NAD\(^+\), FAD, CoA). Their biosynthesis and degradation are therefore of fundamental importance, and disruptions in nucleotide metabolism underlie several diseases and provide targets for anticancer and antiviral drugs.

Key Concept: Purines vs. Pyrimidines

Purines (adenine, guanine) have a two-ring structure (fused pyrimidine and imidazole rings). Pyrimidines (cytosine, uracil, thymine) have a single six-membered ring. A key difference in their biosynthesis:

Purines are built on the ribose sugar (the ring is assembled atom by atom on PRPP)
Pyrimidines are synthesized as the free base first, then attached to ribose-5-phosphate

27.1 Purine Biosynthesis De Novo

The de novo pathway for purine synthesis involves 10 enzymatic steps that build the purine ring on a ribose-5-phosphate scaffold. The committed step is the synthesis of 5-phosphoribosylamine from PRPP and glutamine, catalyzed by glutamine-PRPP amidotransferase (also called PPAT).

The atoms of the purine ring come from multiple sources:

\(N^1\): from aspartate
\(C^2\) and \(C^8\): from \(N^{10}\)-formyl-THF (one-carbon pool)
\(N^3\) and \(N^9\): from glutamine (amide nitrogen)
\(C^4\), \(C^5\), and \(N^7\): from glycine
\(C^6\): from \(\text{CO}_2\)

The pathway produces inosine monophosphate (IMP) as the first complete purine nucleotide. IMP contains the base hypoxanthine and is the branch point for AMP and GMP synthesis.

\[\text{PRPP} + \text{Gln} \xrightarrow{\text{PPAT}} \text{5-Phosphoribosylamine} + \text{Glu} + \text{PP}_i\]

IMP to AMP and GMP

From IMP, two branches lead to the two purine nucleotides:

\[\text{IMP} + \text{Aspartate} + \text{GTP} \rightarrow \text{Adenylosuccinate} \rightarrow \text{AMP} + \text{Fumarate}\]

\[\text{IMP} + \text{NAD}^+ + \text{H}_2\text{O} \rightarrow \text{XMP} \xrightarrow{\text{Gln}, \text{ATP}} \text{GMP}\]

Note the elegant cross-regulation: AMP synthesis requires GTP, and GMP synthesis requires ATP. This reciprocal relationship ensures balanced production of the two purines.

Mathematical Deep Dive: Cost of Purine Biosynthesis

The de novo synthesis of one IMP molecule requires substantial investment:

\[\text{Ribose-5-P} + 2\text{Gln} + \text{Gly} + \text{Asp} + \text{CO}_2 + 2 \times N^{10}\text{-formyl-THF} + 6\text{ATP} \rightarrow \text{IMP}\]

Converting IMP to AMP costs 1 GTP; converting IMP to GMP costs 1 ATP + 1 NAD\(^+\). The total energy cost per AMP is approximately 7 high-energy phosphate bonds, and per GMP approximately 8. This high cost explains the importance of salvage pathways for recycling purine bases.

The regulation of the pathway involves feedback inhibition at multiple points: AMP and GMP both inhibit PPAT (the committed step); AMP inhibits adenylosuccinate synthetase; GMP inhibits IMP dehydrogenase. This ensures appropriate and balanced nucleotide pools.

27.2 Pyrimidine Biosynthesis De Novo

Unlike purines, pyrimidines are synthesized as the free ring first, then attached to ribose-5-phosphate. The pathway produces UMP as the parent pyrimidine nucleotide.

The key steps are:

Carbamoyl phosphate synthetase II (CPS-II) produces carbamoyl phosphate from glutamine (not \(\text{NH}_4^+\)), \(\text{CO}_2\), and 2 ATP. This is the rate-limiting step of pyrimidine synthesis and occurs in the cytosol (unlike CPS-I of the urea cycle, which is mitochondrial).
Aspartate transcarbamoylase (ATCase) condenses carbamoyl phosphate with aspartate to form carbamoyl aspartate.
Dihydroorotase cyclizes carbamoyl aspartate to dihydroorotate.
Dihydroorotate dehydrogenase (mitochondrial inner membrane) oxidizes dihydroorotate to orotate, using ubiquinone as the electron acceptor.
Orotate phosphoribosyltransferase attaches orotate to PRPP, forming orotidine-5'-monophosphate (OMP).
OMP decarboxylase converts OMP to UMP.

\[\text{Gln} + \text{CO}_2 + 2\text{ATP} + \text{Asp} + \text{NAD}^+ + \text{PRPP} \rightarrow \text{UMP} + \text{CO}_2 + \text{Glu} + 2\text{ADP} + \text{P}_i + \text{PP}_i + \text{NADH}\]

In mammals, the first three enzymes (CPS-II, ATCase, dihydroorotase) are part of a single trifunctional polypeptide called CAD. Similarly, orotate phosphoribosyltransferase and OMP decarboxylase form a bifunctional enzyme called UMP synthase.

UMP to Other Pyrimidines

\[\text{UMP} \xrightarrow{\text{kinases}} \text{UDP} \xrightarrow{\text{kinase}} \text{UTP} \xrightarrow{\text{CTP synthetase}} \text{CTP}\]

CTP synthetase converts UTP to CTP using glutamine as the nitrogen donor and ATP as the energy source. This is the only route for CTP synthesis de novo.

27.3 Salvage Pathways

Given the high energy cost of de novo synthesis, cells extensively recycle purine and pyrimidine bases released by nucleic acid degradation. The key salvage enzymes are:

Hypoxanthine-guanine phosphoribosyltransferase (HGPRT):
\(\text{Hypoxanthine} + \text{PRPP} \rightarrow \text{IMP} + \text{PP}_i\)
\(\text{Guanine} + \text{PRPP} \rightarrow \text{GMP} + \text{PP}_i\)
Adenine phosphoribosyltransferase (APRT):
\(\text{Adenine} + \text{PRPP} \rightarrow \text{AMP} + \text{PP}_i\)
Thymidine kinase:
\(\text{Thymidine} + \text{ATP} \rightarrow \text{dTMP} + \text{ADP}\)

27.4 Deoxyribonucleotide Synthesis

DNA synthesis requires deoxyribonucleotides (dNTPs), which are produced from ribonucleotides by ribonucleotide reductase (RNR). This remarkable enzyme reduces the 2'-OH of ribonucleoside diphosphates (NDPs) to form deoxyribonucleoside diphosphates (dNDPs):

\[\text{NDP} + \text{Thioredoxin}_{\text{red}} \xrightarrow{\text{RNR}} \text{dNDP} + \text{Thioredoxin}_{\text{ox}} + \text{H}_2\text{O}\]

RNR has a complex allosteric regulatory system with two types of regulatory sites:

Activity site: ATP activates, dATP inhibits (overall on/off switch)
Specificity site: Determines which substrate is reduced. ATP/dATP favor CDP/UDP reduction; dTTP favors GDP reduction; dGTP favors ADP reduction. This ensures balanced dNTP pools.

27.5 Thymidylate Synthesis

DNA contains thymine (5-methyluracil) rather than uracil. The methyl group is added to dUMP by thymidylate synthase using\(N^5,N^{10}\)-methylene-THF as both the one-carbon donor and the reducing agent:

\[\text{dUMP} + N^5,N^{10}\text{-methylene-THF} \xrightarrow{\text{thymidylate synthase}} \text{dTMP} + \text{DHF}\]

THF must be regenerated from DHF by dihydrofolate reductase (DHFR):

\[\text{DHF} + \text{NADPH} + \text{H}^+ \xrightarrow{\text{DHFR}} \text{THF} + \text{NADP}^+\]

This cycle — thymidylate synthase producing DHF and DHFR regenerating THF — is a critical vulnerability in rapidly dividing cells, making both enzymes prime targets for anticancer and antimicrobial drugs.

Clinical Correlation: Anticancer Drugs Targeting Nucleotide Metabolism

Several widely used chemotherapy agents exploit the vulnerability of nucleotide metabolism in cancer cells:

Methotrexate: A folate analog that potently inhibits DHFR, blocking THF regeneration and thereby inhibiting both thymidylate synthesis and purine synthesis. Used in leukemia, lymphoma, breast cancer, and autoimmune diseases. Leucovorin (folinic acid) rescue can bypass the DHFR block in normal cells.
5-Fluorouracil (5-FU): Converted to 5-FdUMP, which is a suicide inhibitor of thymidylate synthase. It forms a covalent ternary complex with the enzyme and \(N^5,N^{10}\)-methylene-THF, irreversibly blocking dTMP synthesis. Widely used in colorectal and other GI cancers.
6-Mercaptopurine (6-MP): A purine analog activated by HGPRT to 6-thio-IMP, which inhibits multiple steps in purine biosynthesis. Used in acute lymphoblastic leukemia. Patients deficient in thiopurine methyltransferase (TPMT) are at risk of severe toxicity.
Hydroxyurea: Inhibits ribonucleotide reductase by scavenging the essential tyrosyl free radical. Used in CML and sickle cell disease (by increasing fetal hemoglobin).
Mycophenolate mofetil: Inhibits IMP dehydrogenase (IMP \(\rightarrow\) XMP \(\rightarrow\) GMP), selectively affecting lymphocytes that are highly dependent on the de novo pathway. Used as an immunosuppressant in organ transplantation.

The selectivity of these drugs relies on the fact that cancer cells (and immune cells) proliferate more rapidly than most normal cells and therefore have greater demands for nucleotide synthesis. However, the therapeutic window is often narrow, leading to side effects in other rapidly dividing tissues (bone marrow, GI epithelium, hair follicles).

27.6 Purine Degradation

Purine nucleotides are degraded to the free bases hypoxanthine and guanine, which are then oxidized to uric acid by xanthine oxidase:

\[\text{Hypoxanthine} \xrightarrow{\text{xanthine oxidase}} \text{Xanthine} \xrightarrow{\text{xanthine oxidase}} \text{Uric acid}\]

\[\text{Guanine} \xrightarrow{\text{guanase}} \text{Xanthine} \xrightarrow{\text{xanthine oxidase}} \text{Uric acid}\]

In humans, uric acid is the end product of purine catabolism (we lack uricase, which in most other mammals converts uric acid to the more soluble allantoin). Uric acid has limited solubility in body fluids, and when its concentration exceeds the saturation point, it crystallizes as monosodium urate.

Clinical Correlation: Gout and Lesch-Nyhan Syndrome

Gout is caused by hyperuricemia (elevated serum uric acid). Monosodium urate crystals deposit in joints (especially the first metatarsophalangeal joint — podagra), causing intense inflammatory arthritis. Risk factors include purine-rich diet (red meat, organ meats, shellfish), alcohol (especially beer), obesity, and renal insufficiency.

Treatment includes:

Acute attacks: NSAIDs, colchicine (inhibits neutrophil migration), corticosteroids
Chronic management: Allopurinol or febuxostat (xanthine oxidase inhibitors reduce uric acid production)
Uricosuric agents: Probenecid (increases renal uric acid excretion)
Recombinant uricase: Rasburicase/pegloticase for refractory cases

Lesch-Nyhan syndrome is a devastating X-linked recessive disorder caused by complete deficiency of HGPRT. Without this salvage enzyme, purine bases cannot be recycled, leading to:

Massive overproduction of purines de novo (PRPP accumulates, removing feedback inhibition)
Severe hyperuricemia and gout (even in childhood)
Neurological symptoms: intellectual disability, spasticity, and characteristic compulsive self-injurious behavior (lip and finger biting)

The neurological basis of Lesch-Nyhan syndrome remains incompletely understood but involves dopaminergic neuron dysfunction in the basal ganglia. Allopurinol can control hyperuricemia but does not improve the neurological symptoms.

27.7 Pyrimidine Degradation

Pyrimidine degradation, unlike purine degradation, yields highly soluble products that do not cause clinical problems analogous to gout. The pyrimidine ring is opened and degraded:

\[\text{Cytosine} \rightarrow \text{Uracil} \rightarrow \text{Dihydrouracil} \rightarrow \beta\text{-Ureidopropionate} \rightarrow \beta\text{-Alanine} + \text{NH}_4^+ + \text{CO}_2\]

\[\text{Thymine} \rightarrow \text{Dihydrothymine} \rightarrow \beta\text{-Ureidoisobutyrate} \rightarrow \beta\text{-Aminoisobutyrate} + \text{NH}_4^+ + \text{CO}_2\]

\(\beta\)-Alanine can be used in the synthesis of coenzyme A (as part of pantothenate) and in the dipeptide carnosine (\(\beta\)-alanyl-histidine) found in muscle.\(\beta\)-Aminoisobutyrate is excreted in urine and is sometimes used as a marker of DNA turnover.

27.8 Summary of Nucleotide Structures and Nomenclature

Base	Type	Nucleoside	Nucleotide (5'-MP)	In DNA?	In RNA?
Adenine (A)	Purine	Adenosine	AMP	dAMP	AMP
Guanine (G)	Purine	Guanosine	GMP	dGMP	GMP
Cytosine (C)	Pyrimidine	Cytidine	CMP	dCMP	CMP
Uracil (U)	Pyrimidine	Uridine	UMP	—	UMP
Thymine (T)	Pyrimidine	Thymidine	dTMP	dTMP	—
Hypoxanthine	Purine	Inosine	IMP	Intermediate in purine synthesis

For Graduate Students: Nucleotide Metabolism as Antiviral Target

Many antiviral drugs are nucleoside/nucleotide analogs that exploit viral polymerases:

Acyclovir: A guanosine analog selectively phosphorylated by viral thymidine kinase (in HSV/VZV-infected cells). The triphosphate form inhibits viral DNA polymerase and causes chain termination (lacks 3'-OH).
Zidovudine (AZT): A thymidine analog that, after triphosphorylation, inhibits HIV reverse transcriptase. The 3'-azido group prevents chain elongation.
Sofosbuvir: A uridine analog prodrug that inhibits hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. Revolutionized HCV treatment with cure rates exceeding 95%.
Remdesivir: An adenosine analog that inhibits SARS-CoV-2 RNA-dependent RNA polymerase. Causes delayed chain termination by being incorporated into the growing RNA strand and sterically clashing with the polymerase active site at position \(i+3\).

The selectivity of these analogs depends on preferential activation or incorporation by viral enzymes compared to host cell enzymes, providing a therapeutic window. However, resistance mutations in viral polymerases remain a clinical challenge.

27.9 Integration and Regulation Overview

Nucleotide metabolism is tightly integrated with other pathways:

One-carbon metabolism connects amino acid catabolism (serine, glycine) to both purine and thymidylate synthesis through folate cofactors.
The pentose phosphate pathway provides ribose-5-phosphate (for PRPP synthesis) and NADPH (for ribonucleotide reduction and DHFR).
Amino acid metabolism provides glycine, aspartate, and glutamine as building blocks for the purine and pyrimidine rings.
Energy metabolism provides ATP for the many kinase reactions and for de novo synthesis.

Mathematical Deep Dive: Cellular dNTP Pools

Maintaining balanced dNTP concentrations is essential for DNA replication fidelity. Typical intracellular dNTP concentrations in mammalian cells are:

\[\text{dATP} \approx 24\,\mu\text{M}, \quad \text{dTTP} \approx 37\,\mu\text{M}\]

\[\text{dCTP} \approx 29\,\mu\text{M}, \quad \text{dGTP} \approx 5.2\,\mu\text{M}\]

The dGTP pool is notably the smallest. Imbalances in dNTP pools increase mutation rates because DNA polymerase misincorporation probability is proportional to the ratio of incorrect to correct dNTP concentrations:

\[P_{\text{misincorporation}} \propto \frac{[\text{dNTP}_{\text{incorrect}}]}{[\text{dNTP}_{\text{correct}}]}\]

This is why the allosteric regulation of ribonucleotide reductase is so critical: it ensures that all four dNTPs are produced in the proportions needed for accurate DNA replication. Mutations that disrupt RNR regulation are associated with increased mutagenesis and genome instability.

Part V Summary

This part has covered the rich and interconnected world of nitrogen metabolism:

Chapter 23: Amino acid catabolism begins with transamination (PLP-dependent, funneling nitrogen to glutamate) followed by oxidative deamination (glutamate dehydrogenase releasing \(\text{NH}_4^+\)). One-carbon metabolism via THF and SAM connects amino acid catabolism to biosynthetic pathways.
Chapter 24: The urea cycle converts toxic\(\text{NH}_4^+\) to urea through five enzymatic reactions spanning the mitochondria and cytosol, at a cost of 4 high-energy bonds per urea. CPS-I (activated by NAG) is the rate-limiting enzyme.
Chapter 25: Carbon skeletons of amino acids enter central metabolism as seven possible intermediates. Only Leu and Lys are purely ketogenic; most amino acids are glucogenic. Inborn errors (PKU, MSUD, homocystinuria) illustrate the clinical importance of these pathways.
Chapter 26: Humans synthesize 11 nonessential amino acids from metabolic intermediates. Amino acids are precursors for neurotransmitters, heme, creatine, glutathione, NO, and many other molecules.
Chapter 27: Purine nucleotides are built on PRPP (IMP as the branch point); pyrimidines are synthesized as free bases then attached to ribose. Salvage pathways recycle bases. Ribonucleotide reductase provides dNTPs for DNA synthesis. Thymidylate synthase and DHFR are key chemotherapy targets. Purine degradation yields uric acid (gout, Lesch-Nyhan); pyrimidine degradation yields \(\beta\)-alanine.

Key Concept: The Central Role of Glutamate

Glutamate stands at the crossroads of nitrogen metabolism. It is the primary collector of amino groups via transamination, the nitrogen donor for many biosynthetic reactions, the precursor for GABA (the main inhibitory neurotransmitter), a component of glutathione (the cell's primary antioxidant), and the source of ammonium for the urea cycle via glutamate dehydrogenase. Glutamine, its amide derivative, serves as a non-toxic nitrogen transport form in the blood and as a nitrogen donor in nucleotide and amino sugar synthesis. Understanding the pivotal role of the glutamate/glutamine axis is essential for integrating all of nitrogen metabolism.

←Part IV: Lipid Metabolism Course Home Part VI: Metabolic Integration→